Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

Stefania Morganti; Qingchun Jin; Julie Vincuilla; Ryan Buehler; Sean Ryan; Samantha Stokes; Tonia Parker; Elizabeth A Mittendorf; Tari A King; Anna Weiss; Ann H Partridge; Brittany L Bychkovsky; Giuseppe Curigliano; Nabihah Tayob; Nancy U Lin; Judy E Garber; Sara M Tolaney; Filipa Lynce

doi:10.1038/s41523-024-00632-8

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

NPJ Breast Cancer. 2024 Apr 16;10(1):28. doi: 10.1038/s41523-024-00632-8.

Authors

Stefania Morganti^{1

2

3

4}, Qingchun Jin⁵, Julie Vincuilla², Ryan Buehler⁶, Sean Ryan^{1

2}, Samantha Stokes⁴, Tonia Parker^{1

2}, Elizabeth A Mittendorf^{2

3

7}, Tari A King^{2

3

7}, Anna Weiss^{2

3

7

8}, Ann H Partridge^{1

2

3}, Brittany L Bychkovsky^{1

2

3

6}, Giuseppe Curigliano^{9

10}, Nabihah Tayob^{3

5}, Nancy U Lin^{1

2

3}, Judy E Garber^{1

2

3

6}, Sara M Tolaney^{1

2

3}, Filipa Lynce^{11

12

13}

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
³ Harvard Medical School, Boston, MA, USA.
⁴ Broad Institute of MIT and Harvard, Boston, MA, USA.
⁵ Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
⁶ Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.
⁷ Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
⁸ Division of Surgical Oncology, University of Rochester Medical Center, Rochester, NY, USA.
⁹ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
¹⁰ European Institute of Oncology IRCCS, Milan, Italy.
¹¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. filipa_lynce@dfci.harvard.edu.
¹² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. filipa_lynce@dfci.harvard.edu.
¹³ Harvard Medical School, Boston, MA, USA. filipa_lynce@dfci.harvard.edu.

Abstract

Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.